BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis.

This query targets groundbreaking clinical outcomes of CAR-T cell therapy for refractory lupus nephritis, a highly relevant topic in the Arab region due to the high prevalence and severity of SLE.